Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Successful management of therapy‐related chronic myelomonocytic leukemia with cytarabine, aclarubicin, and azacitidine following tegafur/gimeracil/oteracil
View through CrossRef
AbstractA 55‐year‐old man was diagnosed with therapy‐related chronic myelomonocytic leukemia (t‐CMML) after exposure to tegafur/gimeracil/oteracil. Although he was refractory to hydroxyurea and low‐dose cytarabine, combination therapy with cytarabine, aclarubicin and azacitidine (CA‐AZA) provided good disease control, and he underwent allogeneic stem cell transplantation. This report has two key massages. First, tegafur/gimeracil/oteracil may have a potential risk of developing t‐CMML. Second, CA‐AZA therapy may be considered as a therapeutic option for patients with t‐CMML.
Title: Successful management of therapy‐related chronic myelomonocytic leukemia with cytarabine, aclarubicin, and azacitidine following tegafur/gimeracil/oteracil
Description:
AbstractA 55‐year‐old man was diagnosed with therapy‐related chronic myelomonocytic leukemia (t‐CMML) after exposure to tegafur/gimeracil/oteracil.
Although he was refractory to hydroxyurea and low‐dose cytarabine, combination therapy with cytarabine, aclarubicin and azacitidine (CA‐AZA) provided good disease control, and he underwent allogeneic stem cell transplantation.
This report has two key massages.
First, tegafur/gimeracil/oteracil may have a potential risk of developing t‐CMML.
Second, CA‐AZA therapy may be considered as a therapeutic option for patients with t‐CMML.
Related Results
Effect of Sipjeondaebo-Tang on the Pharmacokinetics of S-1, an Anticancer Agent, in Rats Evaluated by Population Pharmacokinetic Modeling
Effect of Sipjeondaebo-Tang on the Pharmacokinetics of S-1, an Anticancer Agent, in Rats Evaluated by Population Pharmacokinetic Modeling
S-1 (TS-1®) is an oral fluoropyrimidine anticancer agent containing tegafur, oteracil, and gimeracil. Sipjeondaebo-tang (SDT) is a traditional oriental herbal medicine that has pot...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Aclarubicin Reduces the Nuclear Mobility of Human DNA Topoisomerase IIβ
Aclarubicin Reduces the Nuclear Mobility of Human DNA Topoisomerase IIβ
DNA topoisomerase II (TOP2) is an enzyme that resolves DNA topological problems arising in various nuclear processes, such as transcription. Aclarubicin, a member of the anthracycl...
Abstract 1150: Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351
Abstract 1150: Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351
Abstract
CPX-351 is a liposomal form encapsulating cytarabine and daunorubicin for treating Acute Myeloid Leukemia (AML) patients. Cytidine Deaminase (CDA) cataboliz...
Stability and visual compatibility of daunorubicin and cytarabine during Y-site administration with selected drugs.
Stability and visual compatibility of daunorubicin and cytarabine during Y-site administration with selected drugs.
e15516 Background: Vyxeos is a daunorubicine plus cytarabine liposome indicated in adults patient with newly diagnosed acute myeloid leukemia with myelodysplasia-related changes (...
Additional Decitabine Did Not Improve Outcomes of Elder Acute Myeloid Leukemia Patients Based on Microtransplantation with Cytarabine and Anthracycline Chemotherapy
Additional Decitabine Did Not Improve Outcomes of Elder Acute Myeloid Leukemia Patients Based on Microtransplantation with Cytarabine and Anthracycline Chemotherapy
Abstract
Acute myeloid leukemia (AML) of older patients is an aggressive malignancy. Despite decitabine is performed some clinic trials in these patients, however th...
Myosin-IIa Is Required for Leukemia Cell Extravasation and Its Inhibition Reduces Leukemia Dissemination and Prolongs Survival in a Mouse Model of Acute Lymphoblastic Leukemia
Myosin-IIa Is Required for Leukemia Cell Extravasation and Its Inhibition Reduces Leukemia Dissemination and Prolongs Survival in a Mouse Model of Acute Lymphoblastic Leukemia
Abstract
Background: Leukemia affects approximately 45,000 people each year in the USA with more than 20,000 fatalities. Many leukemia patients experience initial re...
Hemophagocytic lymphohistiocytosis as an unexpected complication of Venetoclax+Azacitidine in Acute Myeloid Leukemia
Hemophagocytic lymphohistiocytosis as an unexpected complication of Venetoclax+Azacitidine in Acute Myeloid Leukemia
Background: Venetoclax is a drug that targets BCL-2 protein in cancer cells, first approved for chronic lymphocytic leukemia, this drug has showed efficacy also in acute myeloid le...